Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Has Average Price Target of $22.29 According to Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $22.29.

Several brokerages recently issued reports on ARCT. Zacks Research raised Arcturus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. Wall Street Zen raised Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Thursday, October 15th. BTIG Research dropped their target price on Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, September 24th. Finally, Leerink Partners boosted their price objective on shares of Arcturus Therapeutics from $13.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, October 9th.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds have recently made changes to their positions in the company. Versant Capital Management Inc raised its holdings in Arcturus Therapeutics by 648.6% during the 3rd quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company’s stock worth $42,000 after buying an additional 2,627 shares during the period. Two Sigma Securities LLC bought a new stake in Arcturus Therapeutics in the 2nd quarter worth about $80,000. ADAR1 Capital Management LLC purchased a new stake in Arcturus Therapeutics during the first quarter valued at $116,000. Diversify Advisory Services LLC purchased a new position in shares of Arcturus Therapeutics in the 2nd quarter worth approximately $91,000. Finally, Diversify Wealth Management LLC acquired a new position in shares of Arcturus Therapeutics during the 1st quarter worth about $133,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

ARCT opened at $10.35 on Friday. The stock has a market capitalization of $294.15 million, a P/E ratio of -3.36 and a beta of 2.62. The business’s 50-day simple moving average is $13.10 and its 200-day simple moving average is $9.05. Arcturus Therapeutics has a one year low of $5.50 and a one year high of $17.96.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, November 5th. The biotechnology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.43. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%. The business had revenue of $18.30 million during the quarter, compared to analysts’ expectations of $8.00 million. On average, equities research analysts forecast that Arcturus Therapeutics will post -3.48 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company’s platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company’s development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.